Anthony J. Polverino
Director/Board Member chez BRAINSTORM CELL THERAPEUTICS INC.
Fortune : 14 667 $ au 31/03/2024
Profil
Dr. Anthony J.
Polverino is an Independent Director at Brainstorm Cell Therapeutics, Inc. He is on the Board of Directors at Brainstorm Cell Therapeutics, Inc. Dr. Polverino was previously employed as a Chief Scientific Officer & EVP-Early Development by Zymeworks BC, Inc., a Chief Scientific Officer by Kite Pharma, Inc., and an Executive Director-Therapeutic Innovation Unit by Amgen, Inc. He received his undergraduate degree from the University of Adelaide and a doctorate degree from Flinders University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/10/2023 | 25 960 ( 0,05% ) | 14 667 $ | 31/03/2024 |
Postes actifs de Anthony J. Polverino
| Sociétés | Poste | Début |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Director/Board Member | 05/02/2018 |
Anciens postes connus de Anthony J. Polverino
| Sociétés | Poste | Fin |
|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 19/01/2022 |
| KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 01/01/2018 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formation de Anthony J. Polverino
| University of Adelaide | Undergraduate Degree |
| Flinders University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
